

DEPARTMENT OF DEFENSE

Defense Health Agency

Intent to Grant an Exclusive License for U.S. Government-Owned Invention

AGENCY: Defense Health Agency, DoD.

ACTION: Notice.

SUMMARY: In accordance with applicable laws and regulations, announcement is made of the intent to grant an exclusive within a field of use, royalty-bearing, revocable license.

ADDRESSES: Commander, U.S. Army Medical Research and Development Command,
ATTN: Director, Office of Research and Technology Applications, 1520 Freedman Drive, Suite
227, Fort Detrick, MD 21702-5012.

FOR FURTHER INFORMATION CONTACT: Dr. Paul Michaels, Office of Research &
Technology Applications, (301) 619-4145. For patent issues, Ms. Leigh Callander, Supervisory
Patent Attorney, (301) 619-7808.

SUPPLEMENTARY INFORMATION: In accordance with 35 U.S.C. 209 (e) and 37 CFR
404.7 (a)(1)(i), announcement is made of the intent to grant an exclusive within a field of use,
royalty-bearing, revocable biological materials license to legacy vaccines including: Equine
Encephalitis inactivated virus vaccine (IND 266), Q Fever inactivated virus vaccine (IND 610),
Rift Valley Fever inactivated virus vaccine (IND 365), Tularemia live attenuated virus vaccine
(IND 157; IND 11825), Venezuelan Equine Encephalitis live attenuated virus vaccine (IND
142), Venezuelan Equine Encephalitis inactivated virus vaccine (IND 914), Chikungunya live
attenuated virus vaccine (IND 2426), and Western Equine Encephalitis inactivated virus vaccine

(IND 2013) to Defender Pharmaceuticals, having its principal place of business at 12935 North Outer Forty Road, Suite 212, St. Louis, Missouri 63141.

Anyone wishing to object to grant of this license can file written objections along with supporting evidence, if any, within 15 days from the date of this publication. Written objections are to be filed with the Director, Office of Research and Technology Applications (see **ADDRESSES**).